Drybench Patent.
SELINEXOR, NDA 212306
The patents and exclusivities FDA's Orange Book lists for NDA 212306 as captured on 14 October 2026, each date named by its rule and its rows, and any rows of FDA's Paragraph IV list captured on 17 October 2026 that give this NDA's number. Listed protection is a range of dates, never one date.
FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
- Paragraph IV list captured
- 17 October 2026
- Last checked
- 30 October 2026
- Data-branch commit
- dadcab56563716abea6c5e31a5e1970080c778ef
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
Listed protection
Listed dates run from 3 Jul 2026 to 14 Aug 2035, each by its own rule; no one date stands for this product.
- Earliest listed date
- 3 Jul 2026ODE* exclusivityRule R3 · Products 002, 003, 004, 005, 006
Source lines
exclusivity.txt lines 1,050, 1,053, 1,056, 1,059, 1,062
- Latest listed date
- 14 Aug 2035US 11,807,629, substance patentRule R1 · Products 005, 006
Source lines
patent.txt lines 13,920, 13,939
- Latest substance patent
- 14 Aug 2035US 11,807,629, substance patentRule R1 · Products 005, 006
Source lines
patent.txt lines 13,920, 13,939
- Latest listed patent
- 14 Aug 2035US 11,807,629, substance patentRule R1 · Products 005, 006
Source lines
patent.txt lines 13,920, 13,939
- Latest exclusivity
- 18 Dec 2027ODE-346 exclusivityRule R3 · Product 001
Source lines
exclusivity.txt line 1,048
Listed dates of other NDAs in the same years:20262027203220332035
97 use-code patents, blocking the coded use only
Products
Each product number FDA lists under NDA 212306, as listed. The sections below name products by these numbers.
Product 001 · XPOVIO
- Dosage form; route
- TABLET;
ORAL - Strength
- 20MG
- Approval date as listed
- 3 Jul 2019
- Type as listed
- RX
- Applicant as listed
- KARYOPHARM THERAPEUTICS INC
Product 002 · XPOVIO
- Dosage form; route
- TABLET;
ORAL - Strength
- 40MG
- Approval date as listed
- 15 Apr 2021
- Type as listed
- RX
- Applicant as listed
- KARYOPHARM THERAPEUTICS INC
Product 003 · XPOVIO
- Dosage form; route
- TABLET;
ORAL - Strength
- 50MG
- Approval date as listed
- 15 Apr 2021
- Type as listed
- RX
- Applicant as listed
- KARYOPHARM THERAPEUTICS INC
Product 004 · XPOVIO
- Dosage form; route
- TABLET;
ORAL - Strength
- 60MG
- Approval date as listed
- 15 Apr 2021
- Type as listed
- RX
- Applicant as listed
- KARYOPHARM THERAPEUTICS INC
Product 005 · XPOVIO
- Dosage form; route
- TABLET;
ORAL - Strength
- 10MG
- Approval date as listed
- 10 Mar 2025
- Type as listed
- RX
- Applicant as listed
- KARYOPHARM THERAPEUTICS INC
Product 006 · XPOVIO
- Dosage form; route
- TABLET;
ORAL - Strength
- 80MG
- Approval date as listed
- 20 Oct 2025
- Type as listed
- RX
- Applicant as listed
- KARYOPHARM THERAPEUTICS INC
Listed patents
Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.
21 entries from 115 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.
US 10,544,108, use patent
patent.txt lines 13,833, 13,853, 13,872, 13,891, 13,910, 13,929- Expiry as listed
- 26 Jul 2032
- Rule
- R1
- Flags
- use code U-2584
- Product numbers
- 001, 002, 003, 004, 005, 006
US 10,544,108, use patent
patent.txt lines 13,834, 13,854, 13,873, 13,892, 13,911, 13,930- Expiry as listed
- 26 Jul 2032
- Rule
- R1
- Flags
- use code U-3018
- Product numbers
- 001, 002, 003, 004, 005, 006
US 11,034,660, use patent
patent.txt lines 13,835, 13,855, 13,874, 13,893, 13,912, 13,931- Expiry as listed
- 26 Jul 2032
- Rule
- R1
- Flags
- use code U-2584
- Product numbers
- 001, 002, 003, 004, 005, 006
US 11,034,660, use patent
patent.txt lines 13,836, 13,856, 13,875, 13,894, 13,913, 13,932- Expiry as listed
- 26 Jul 2032
- Rule
- R1
- Flags
- use code U-3018
- Product numbers
- 001, 002, 003, 004, 005, 006
US 11,787,771, use patent
patent.txt line 13,842- Expiry as listed
- 26 Jul 2032
- Rule
- R1
- Flags
- use code U-2855
- Product numbers
- 001
US 11,787,771, use patent
patent.txt lines 13,841, 13,861, 13,880, 13,899, 13,918, 13,937- Expiry as listed
- 26 Jul 2032
- Rule
- R1
- Flags
- use code U-2584
- Product numbers
- 001, 002, 003, 004, 005, 006
US 11,787,771, use patent
patent.txt lines 13,843, 13,862, 13,881, 13,900, 13,919, 13,938- Expiry as listed
- 26 Jul 2032
- Rule
- R1
- Flags
- use code U-3018
- Product numbers
- 001, 002, 003, 004, 005, 006
US 12,291,508, use patent
patent.txt lines 13,845, 13,864, 13,883, 13,902, 13,921, 13,940- Expiry as listed
- 26 Jul 2032
- Rule
- R1
- Flags
- use code U-2584
- Product numbers
- 001, 002, 003, 004, 005, 006
US 12,291,508, use patent
patent.txt lines 13,846, 13,865, 13,884, 13,903, 13,922, 13,941- Expiry as listed
- 26 Jul 2032
- Rule
- R1
- Flags
- use code U-3018
- Product numbers
- 001, 002, 003, 004, 005, 006
US 9,079,865, use patent
patent.txt lines 13,848, 13,867, 13,886, 13,905, 13,924, 13,943- Expiry as listed
- 26 Jul 2032
- Rule
- R1
- Flags
- use code U-2584
- Product numbers
- 001, 002, 003, 004, 005, 006
US 9,079,865, use patent
patent.txt lines 13,849, 13,868, 13,887, 13,906, 13,925, 13,944- Expiry as listed
- 26 Jul 2032
- Rule
- R1
- Flags
- use code U-3018
- Product numbers
- 001, 002, 003, 004, 005, 006
US 9,714,226, substance and product patent
patent.txt lines 13,850, 13,869, 13,888, 13,907, 13,926, 13,945- Expiry as listed
- 26 Jul 2032
- Rule
- R1
- Flags
- substance · product
- Product numbers
- 001, 002, 003, 004, 005, 006
US 8,999,996, substance and product patent
patent.txt lines 13,847, 13,866, 13,885, 13,904, 13,923, 13,942- Expiry as listed
- 3 Jul 2033
- Rule
- R1
- Flags
- substance · product
- Product numbers
- 001, 002, 003, 004, 005, 006
US 10,519,139, substance and product and use patent
patent.txt lines 13,831, 13,851, 13,870, 13,889, 13,908, 13,927- Expiry as listed
- 14 Aug 2035
- Rule
- R1
- Flags
- substance · product · use code U-2584
- Product numbers
- 001, 002, 003, 004, 005, 006
US 10,519,139, substance and product and use patent
patent.txt lines 13,832, 13,852, 13,871, 13,890, 13,909, 13,928- Expiry as listed
- 14 Aug 2035
- Rule
- R1
- Flags
- substance · product · use code U-3018
- Product numbers
- 001, 002, 003, 004, 005, 006
US 11,746,102, use patent
patent.txt lines 13,837, 13,857, 13,876, 13,895, 13,914, 13,933- Expiry as listed
- 14 Aug 2035
- Rule
- R1
- Flags
- use code U-2584
- Product numbers
- 001, 002, 003, 004, 005, 006
US 11,746,102, use patent
patent.txt lines 13,838, 13,858, 13,877, 13,896, 13,915, 13,934- Expiry as listed
- 14 Aug 2035
- Rule
- R1
- Flags
- use code U-3018
- Product numbers
- 001, 002, 003, 004, 005, 006
US 11,753,401, product and use patent
patent.txt lines 13,839, 13,859, 13,878, 13,897, 13,916, 13,935- Expiry as listed
- 14 Aug 2035
- Rule
- R1
- Flags
- product · use code U-2584
- Product numbers
- 001, 002, 003, 004, 005, 006
US 11,753,401, product and use patent
patent.txt lines 13,840, 13,860, 13,879, 13,898, 13,917, 13,936- Expiry as listed
- 14 Aug 2035
- Rule
- R1
- Flags
- product · use code U-3018
- Product numbers
- 001, 002, 003, 004, 005, 006
US 11,807,629, substance and product patent
patent.txt lines 13,844, 13,863, 13,882, 13,901- Expiry as listed
- 14 Aug 2035
- Rule
- R1
- Flags
- substance · product
- Product numbers
- 001, 002, 003, 004
US 11,807,629, substance patent
patent.txt lines 13,920, 13,939- Expiry as listed
- 14 Aug 2035
- Rule
- R1
- Flags
- substance
- Product numbers
- 005, 006
Listed exclusivities
Each exclusivity FDA lists for NDA 212306, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.
ODE* exclusivity
exclusivity.txt lines 1,050, 1,053, 1,056, 1,059, 1,062- Date
- 3 Jul 2026
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 002, 003, 004, 005, 006
ODE-257 exclusivity
exclusivity.txt line 1,046- Date
- 3 Jul 2026
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 001
ODE* exclusivity
exclusivity.txt lines 1,051, 1,054, 1,057, 1,060- Date
- 22 Jun 2027
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 002, 003, 004, 005
ODE-310 exclusivity
exclusivity.txt line 1,047- Date
- 22 Jun 2027
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 001
ODE* exclusivity
exclusivity.txt lines 1,049, 1,052, 1,055, 1,058, 1,061- Date
- 18 Dec 2027
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 002, 003, 004, 005, 006
ODE-346 exclusivity
exclusivity.txt line 1,048- Date
- 18 Dec 2027
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 001
Paragraph IV list rows giving NDA 212306
The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 212306, each cell as listed.
Rows with no NDA number this page can match are kept apart on the list page; some may concern this product.
No row of the Paragraph IV list captured on 17 October 2026 gives NDA 212306 in its RLD/NDA cell. This does not mean no certification was submitted or that no application challenges a patent listed here.
Notes from the trace
- R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.
Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week